Consistent with this, the treatment of MetS patients with the AT1 blocker irbesartan induced a significant reduction of blood pressure together with a reduction in cardiovascular risk factors: HDL cholesterol, serum triglycerides, fasting blood glucose, and waist circumference [56]. Here, AGTR1 is linked to metabolic syndrome.